Toyota Motor Corp. will resume production in all of its automotive manufacturing plants around the world for the first time since February when its plant in Venezuela restarts operations on Monday.
The Venezuelan plant, where Toyota produced 416 vehicles in 2019, is the last where output had remained suspended due to the pandemic.
Output in over 20 other countries has plants resumed in stages, while not returning to pre-coronavirus levels.
Toyota plans to gradually boost output to meet what it expects to be a recovering global auto demand.
The Japanese carmaker manufactured about 5.63 million vehicles overseas last year.
Toyota's overseas output tumbled 66.2 percent in April from a year earlier and was a 53.0 percent decline in May.
The company expects domestic production volume in July to be 10 percent down from its initial projection.


Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



